- Details
- Neeraj Agarwal discusses a post-hoc analysis of the TALAPRO-2 Phase III study, which evaluates the efficacy of talazoparib and enzalutamide in metastatic castrate-resistant prostate cancer patients with prior ARPI or docetaxel treatment. The analysis shows promising results for the combination therapy, particularly in patients with HRR-deficient tumors. Dr. Agarwal emphasizes the potential benefit...
|
- Details
- Oliver Sartor interviews Neeraj Agarwal about the CONTACT-02 trial, which compares cabozantinib plus atezolizumab to second ARPI in metastatic castrate-resistant prostate cancer patients. Dr. Agarwal presents the final overall survival results from the study, which shows improved progression-free survival with the combination therapy, particularly in patients with liver or bone metastasis. While o...
|
- Details
- In this conversation, Fred Saad discusses the PEACE-3 trial results. The study compares enzalutamide plus radium-223 versus enzalutamide alone in metastatic castration-resistant prostate cancer patients with bone metastases. Dr. Saad discusses the trial's design, highlighting significant improvements in radiographic progression-free survival and overall survival with the combination therapy. They...
|
- Details
- Nicholas James and Minal Padden-Modi discuss the STAMPEDE2 trial Arm P, which examines the use of upfront accelerated lutetium-PSMA-617 in metastatic hormone-sensitive prostate cancer. Dr. Padden-Modi outlines the trial design, which randomizes patients to standard of care with or without lutetium-PSMA-617, administered in an accelerated schedule. The trial includes an imaging sub-study to evaluat...
|
- Details
- Vincenza Conteduca discusses the RAPSON trial, which compares treatment sequencing of radium-223 and docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed on androgen receptor pathway inhibitors. Dr. Conteduca discusses the trial design, which randomizes patients to receive either radium-223 followed by docetaxel or vice versa. The primary endpoint is ch...
|
- Details
- Neeraj Agarwal interviews Fred Saad about the Phase III ARANOTE trial. The study investigates darolutamide plus ADT versus placebo plus ADT in metastatic hormone-sensitive prostate cancer. Dr. Saad discusses the trial's design, patient demographics, and key findings. The results show significant improvements in radiographic progression-free survival, time to mCRPC, pain progression, and PSA respon...
|
- Details
- Ashley Ross and David Morris discuss the use of the Decipher ® Genomic Classifier in metastatic hormone-sensitive prostate cancer (mHSPC). They explore how Decipher ® can help stratify patients and guide treatment decisions, particularly in choosing between monotherapy, doublet, or triplet therapies. The discussion covers the STAMPEDE trial data, showing Decipher's ® ability to predict treatment s...
|
- Details
- Oliver Sartor interviews Bertrand Tombal about the PEACE-3 trial. The study investigates the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer. Dr. Tombal discusses the trial design, results, and implications. The study demonstrates significant improvements in radiographic progression-free survival an...
|
- Details
- Leslie Ballas interviews Hoda Abdel-Aty about the STAMPEDE2 SABR trial, a Phase III randomized study investigating stereotactic ablative body radiotherapy in newly diagnosed oligometastatic prostate cancer patients starting androgen deprivation therapy. Dr. Abdel-Aty discusses the trial design, which compares standard-of-care treatment with or without SABR to metastases. The study defines oligomet...
|
- Details
- Neeraj Agarwal interviews Arun Azad about the UpFrontPSMA study. Dr. Azad discusses the randomized Phase II trial comparing sequential lutetium-PSMA-617 and docetaxel versus docetaxel alone in metastatic hormone-sensitive prostate cancer (mHSPC). The study demonstrates significant improvements in the primary endpoint of undetectable PSA at 48 weeks and several secondary endpoints with the addition...
|
